Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cerus to Present at the Baird 2018 Global Healthcare Conference By: Cerus Corporation via Business Wire News Releases August 30, 2018 at 08:30 AM EDT Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ vice president, finance and chief financial officer, will present and provide a corporate update at the Baird 2018 Global Healthcare Conference in New York City on Thursday, September 6, 2018 at 8:30 a.m. ET. A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event. ABOUT CERUS Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. View source version on businesswire.com: https://www.businesswire.com/news/home/20180830005214/en/ Contacts: Cerus CorporationTim Lee, 925-288-6137Investor Relations Director Related Stocks: Cerus Corp Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Cerus to Present at the Baird 2018 Global Healthcare Conference By: Cerus Corporation via Business Wire News Releases August 30, 2018 at 08:30 AM EDT Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ vice president, finance and chief financial officer, will present and provide a corporate update at the Baird 2018 Global Healthcare Conference in New York City on Thursday, September 6, 2018 at 8:30 a.m. ET. A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event. ABOUT CERUS Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. View source version on businesswire.com: https://www.businesswire.com/news/home/20180830005214/en/ Contacts: Cerus CorporationTim Lee, 925-288-6137Investor Relations Director Related Stocks: Cerus Corp